First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639
Authors:
Manuel Pazos
Brian Estrella
Ted B. Piorczynski
Seda S. Tolu
Wenxuan Huang
Yun Kyoung Ryu
Jennifer E. Amengual
Affiliated Authors:
Manuel Pazos
Brian Estrella
Ted B. Piorczynski
Seda S. Tolu
Wenxuan Huang
Yun Kyoung Ryu
Jennifer E. Amengual
Columbia Affiliation:
Subjects:
Role of Histone Deacetylases in Cellular Regulation (OpenAlex Topic)
Protein Arginine Methylation in Mammals (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-186639
DOI:
10.1182/blood-2023-186639
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: